Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was among the world's best-selling medicines in the depths of the pandemic in 2021.

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled

Moderna , Inc. (NASDAQ:MRNA) today confirmed that it has won a tender to supply its mRNA COVID-19 vaccine in the European Union (EU), Norway, and North Macedonia. The agreement, valid for up to four years,